Mesoblast (STU:LWB) Cyclically Adjusted PB Ratio: (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:LWB Mesoblast Ltd STU:LWB
52 GF Score
Price €1.22
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Mesoblast Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Mesoblast  (STU:LWB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Mesoblast Cyclically Adjusted PB Ratio Related Terms


Mesoblast Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Mesoblast's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Cyclically Adjusted PB Ratio Chart

Mesoblast Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 0.65 0.62 1.11 0.00

Mesoblast Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.11 0.00 1.83 0.00 0.00

STU:LWB vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Mesoblast's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mesoblast Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Mesoblast's Cyclically Adjusted PB Ratio falls into.


STU:LWB
52GF Score
Mesoblast Ltd STU:LWB
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Mesoblast's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Mesoblast's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/137.0353*137.0353
=0.000

Current CPI (Mar. 2026) = 137.0353.

Mesoblast Quarterly Data

Book Value per Share CPI Adj_Book
201606 1.157 0.000
201609 1.128 0.000
201612 1.131 0.000
201703 1.108 0.000
201706 1.016 0.000
201709 0.000 0.000
201712 0.979 0.000
201803 0.904 0.000
201806 0.925 0.000
201809 0.888 0.000
201812 0.879 0.000
201903 0.849 0.000
201906 0.815 0.000
201909 0.819 0.000
201912 0.796 0.000
202003 0.779 0.000
202006 0.797 0.000
202009 0.740 0.000
202012 0.689 0.000
202103 0.739 0.000
202106 0.706 0.000
202109 0.696 0.000
202112 0.693 0.000
202203 0.685 0.000
202206 0.686 0.000
202209 0.680 0.000
202212 0.608 0.000
202303 0.580 0.000
202306 0.540 0.000
202309 0.000 0.000
202312 0.460 0.000
202403 0.000 0.000
202406 0.391 0.000
202409 0.000 129.143 0.000
202412 0.381 130.173 0.401
202503 0.000 131.042 0.000
202506 0.405 131.551 0.422
202509 0.000 133.771 0.000
202512 0.381 135.069 0.387
202603 0.000 137.035 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
52GF Score

Get the complete analysis for STU:LWB

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.22
Price